Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-Year report

American Journal of Transplantation

Volumn 6, Issue 6, 2006, Pages 1377-1386

  Kobashigawa, J A ^a   Miller, L W ^b   Russell, S D ^c   Ewald, G A ^d   Zucker, M J ^e   Goldberg, L R ^f   Eisen, H J ^g   Salm, K ^h   Tolzman, D ^h   Gao, J ⁱ   Fitzsimmons, W ^h   First, R ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c JOHNS HOPKINS HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g TEMPLE UNIVERSITY   (United States)

^h ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

ⁱ EMMES CORPORATION   (United States)

Author keywords

Cyclosporine; Immunosuppression; Outcomes; Rejection; Sirolimus; Tacrolimus

Indexed keywords

ANTILIPEMIC AGENT; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DACLIZUMAB; GANCICLOVIR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; TRIACYLGLYCEROL; VALGANCICLOVIR;

ADULT; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CUSHINGOID SYNDROME; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GINGIVA HYPERTROPHY; GRAFT REJECTION; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HEMOGLOBIN BLOOD LEVEL; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERSTITIAL PNEUMONIA; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LEUKOPENIA; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MYCOSIS; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECIPIENT; REFRACTORY PERIOD; SKIN CANCER; THROMBOCYTE COUNT; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS INFECTION; WOUND HEALING IMPAIRMENT;

ADULT; ANTILIPEMIC AGENTS; ANTIVIRAL AGENTS; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; NEOPLASMS; PATIENT SELECTION; POSTOPERATIVE COMPLICATIONS; SIROLIMUS; TREATMENT OUTCOME; UNITED STATES;

EID: 33745393847     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01290.x     Document Type: Article

References (28)

1. Plosker GL, Foster RH. Tacrolimus: A further update of its pharmacology and therapeutic use in the management of organ transplantation. Drugs 2000; 59: 323-389.
2. Starzl TE, Todo S, Fung J, Demtris AJ, Venkataramman R, Jain A. FK506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000-1004.
3. Baran DA, Galin I, Sandler D et al. Tacrolimus in cardiac transplantation: Efficacy and safety of a novel dosing protocol. Transplantation 2002; 74: 1136-1141.
4. Armitage JM, Kormos RL, Morita S et al. Clinical trial of FK506 immunosuppression in adult cardiac transplantation. Ann Thorac Surg 1992; 54: 205-211.
5. Pham SM, Kormos RL, Hattler BG et al. A prospective trial of tacrolimus (FK506) in clinical heart transplantation: Intermediate-term results. J Thorac Cardiovasc Surg 1996; 111: 764-772.
6. Taylor DO, Barr ML, Radovancevic B et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: Decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336-345.
7. Reichart B, Meiser B, Vigano M et al. European multicenter tacrolimus (FK506) heart pilot study: One-year results - European tacrolimus multicenter heart study group. J Heart Lung Transplant 1998; 17: 775-781.
8. Kobashigawa J, Miller L, Renlund D et al. A randomized active-control trial of mycophenolate mofetil in heart transplant recipients. Transplantation 1998; 66: 507-515.
9. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years. A randomized clinical trial. Circulation 2004; 110: r10-r16.
10. Eisen HJ, Tuczu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients. N Engl J Med 2003; 349: 847-858.
11. Billingham ME, Cary NR, Hammond EM et al. A working formulation for standardization of nomenclature in the diagnosis of heart and lung rejection study group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587-593.
12. Hertz Ml, Taylor DO, Trulock EP et al. The Registry of the International Society for Heart and Lung Transplantation: Nineteenth official report - 2002. J Heart Lung Transplant 2002; 21: 950-970.
13. Jurcevic S, Dunn MJ, Crisp S et al. A new enzyme-linked immunoabsorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 1998; 65: 1197-1202.
14. Kobashigawa JA, Moriguchi JD, Takemoto S et al. First year results of a randomized trial of tacrolimus vs. neoral cyclosporine in heart transplant patients [abstract]. J Heart Lung Transplant 2000; 19: 47.
15. De Bonis M, Reynolds L, Barros J, Madden BP. Tacrolimus as a rescue immunosuppressant after heart transplantation. Eur J Cardiothorac Surg 2001; 19: 690-695.
16. Yamani MH, Starling RC, Pelegrin D et al. Efficacy of tacrolimus in patients with steroid-resistant cardiac allograft cellular rejection. J Heart Lung Transplant 2000; 19: 337-342.
17. Mathieu P, Carrier M, White M et al. Conversion of cyclosporine A to tacrolimus following heart transplantation. Can J Cardiol 1999; 15: 1229-1232.
18. Meiser BM, Überfuhr P, Fuchs A et al. Tacrolimus: A superior agent to OKT3 for treating cases of persistent rejection after intrathoracic transplantation. J Heart Lung Transplant 1997; 16: 795-800.
19. Escobar A, Ventura HO, Stapleton DD et al. Cardiac allograft vasculopathy assessed by intravascular ultrasonography and nonimmunologic risk factors. Am J Cardiol 1994; 74: 1042-1046.
20. Kobashigawa J, Katznelson S, Laks H et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
21. Meisner BM, Überfuhr P, Fuchs A et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17: 782-788.
22. Marelli S, Laks H, Patel B et al. Heart transplantation in patients with diabetes mellitus in the current era. J Heart Lung Transplant 2003; 22: 1091-1097.
23. Czerny M, Sahin V, Fashing P et al. The impact of diabetes mellitus at the time of heart transplantation on long-term survival. Diabetologia 2002; 45: 1498-1508.
24. Lang CC, Beniaminovitz A, Edwards N, Mancini DM. Morbidity and mortality in diabetic patients following cardiac transplantation. J Heart Lung Transplant 2003; 22: 244-249.
25. Teebken OE, Struber M, Harringer W et al. Primary immunosuppression with tacrolimus and mycophenolate mofetil vs cyclosporine and azathioprine in heart transplant recipients. Transplant Proc 2002; 34: 1265-1268.
26. Keogh A, The Sirolimus Cardiac Transplant Trial Group. Sirolimus immunotherapy reduces the rates of cardiac allograft rejection: 6-month results from a phase 2, open-label study [abstract]. Am J Transplant 2002; 2 (Suppl 3): 246.
27. Kauffman HM, Cherikh WSS, McBride MA et al. TOR inhibitor maintenance immunosuppression is associated with a reduced incidence of post-transplant malignancies [abstract]. Transplant 2004; 78: 30.
28. Hesselink DA, van Gelder T. The influence of cyclosporine on mycophenolic acid concentrations: A review. Transplant Rev 2003; 17: 158-163.